Galera Therapeutics Q2 EPS $(0.48) Misses $(0.43) Estimate, Cash & Equivalents Including Short-Term Investments Peg At $38.76M As Of Quarter-End
Portfolio Pulse from Benzinga Newsdesk
Galera Therapeutics reported Q2 losses of $(0.48) per share, missing the analyst consensus estimate of $(0.44) by 9.09%. This is an 11.11% increase over losses from the same period last year. The company's cash and equivalents, including short-term investments, were pegged at $38.76M at the end of the quarter.
August 14, 2023 | 11:27 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Galera Therapeutics' Q2 earnings per share missed estimates, which could negatively impact investor sentiment.
Galera Therapeutics reported a larger loss than expected for Q2, which could lead to a decrease in investor confidence and a potential drop in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100